Shijiazhuang Yiling Pharmaceutical (SHE:002603) through unit Wanyang Hengshui Pharmaceutical, received a certificate of suitability from the European Union's pharmaceutical regulator for the active pharmaceutical ingredient, Letrozole, according to a Thursday filing on the Shenzhen bourse.
The API, which inhibits estrogen synthesis, is used in the treatment of breast cancer.
The Chinese pharmaceutical company's shares rose 1% at the close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.